China has pledged to continue to advance a trial program on centralized medicine procurement and use to ensure patients' access to high-quality medicine at lower prices.
Fifteen new measures have been adopted at an executive meeting of the State Council to tackle bottlenecks in the implementation of the trial program, said Wang Hesheng, deputy head of the National Health Commission, at a press conference Wednesday.
The measures include optimizing the mode of centralized The measures include optimizing the mode of centralized medicine procurement, expanding the coverage of drugs, improving medicine quality and stabilizing medicine supply, said Wang.
In 2018, 11 cities that ran the trial program saw an average price reduction of 52 percent in 25 selected medicines.
The trial program has also promoted high-quality development of pharmaceutical enterprises by reducing their sales expenses, according to Chen Jinfu, deputy head of the National Healthcare Security Administration.
The State Council approved in January this year state-run centralized medicine procurement in 11 pilot cities in an effort to deepen the reform of the medical and health sector and optimize the pricing system of drugs.
（source:ourjiangsu.com)
